{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:31:21Z","timestamp":1794976281113,"version":"4.9.1"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","award":["RG14-15"],"award-info":[{"award-number":["RG14-15"]}],"id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,9,8]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Accelerated lung function decline has been associated with increased risk of cardiovascular disease (CVD) in a general population, but little is known about this association in chronic obstructive pulmonary disease (COPD). We investigated the association between accelerated lung function decline and CVD outcomes and mortality in a primary care COPD population.<\/jats:p>\n                  <jats:p>\n                    COPD patients without a history of CVD were identified in the Clinical Practice Research Datalink (CPRD)-GOLD primary care dataset (n=36\u200a382). Accelerated decline in forced expiratory volume in 1\u2005s (FEV\n                    <jats:sub>1<\/jats:sub>\n                    ) was defined using the fastest quartile of the COPD population's decline. A Cox regression was used to assess the association between baseline accelerated FEV\n                    <jats:sub>1<\/jats:sub>\n                    decline and a composite CVD outcome over follow-up (myocardial infarction, ischaemic stroke, heart failure, atrial fibrillation, coronary artery disease and CVD mortality). The model was adjusted for age, sex, smoking status, body mass index, history of asthma, hypertension, diabetes, statin use, Modified Medical Research Council (mMRC) dyspnoea score, exacerbation frequency and baseline FEV\n                    <jats:sub>1<\/jats:sub>\n                    % predicted.\n                  <\/jats:p>\n                  <jats:p>\n                    6110 COPD patients (16.8%) had a CVD event during follow-up; median length of follow-up was 3.6\u2005years (interquartile range (IQR) 1.7\u20136.1 years). Median rate of FEV\n                    <jats:sub>1<\/jats:sub>\n                    decline was \u201319.4\u2005mL\u00b7year\n                    <jats:sup>\u22121<\/jats:sup>\n                    (IQR \u201340.5\u20131.9); 9095 patients (25%) had accelerated FEV\n                    <jats:sub>1<\/jats:sub>\n                    decline (&gt;\u202f\u201340.5\u2005mL\u00b7year\n                    <jats:sup>\u22121<\/jats:sup>\n                    ), 27\u200a287 (75%) did not (\u2264\u202f\u201340.5\u2005mL\u00b7year\n                    <jats:sup>\u22121<\/jats:sup>\n                    ). Risk of CVD and mortality was similar between patients with and without accelerated FEV\n                    <jats:sub>1<\/jats:sub>\n                    decline (HR\n                    <jats:sub>adj<\/jats:sub>\n                    0.98, 95% CI 0.90\u20131.06). Corresponding risk estimates were 0.99 (95% CI 0.83\u20131.20) for heart failure, 0.89 (95% CI 0.70\u20131.12) for myocardial infarction, 1.01 (95% CI 0.82\u20131.23) for stroke, 0.97 (95% CI 0.81\u20131.15) for atrial fibrillation, 1.02 (95% CI 0.87\u20131.19) for coronary artery disease and 0.94 (95% CI 0.71\u20131.25) for CVD mortality. Rather, risk of CVD was associated with a mMRC score \u22642 and two or more exacerbations in the year prior.\n                  <\/jats:p>\n                  <jats:p>\n                    CVD outcomes and mortality were associated with exacerbation frequency and severity and increased mMRC dyspnoea score but not with accelerated FEV\n                    <jats:sub>1<\/jats:sub>\n                    decline.\n                  <\/jats:p>","DOI":"10.1183\/13993003.00918-2020","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T16:50:16Z","timestamp":1600966216000},"page":"2000918","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Accelerated FEV\n                    <sub>1<\/sub>\n                    decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients"],"prefix":"10.1183","volume":"57","author":[{"given":"Hannah R.","family":"Whittaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-0860","authenticated-orcid":false,"given":"Ann","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-3896","authenticated-orcid":false,"given":"Deborah","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Kiddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K.","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"2026061109101802000_57.3.2000918.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028150"},{"key":"2026061109101802000_57.3.2000918.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105482"},{"key":"2026061109101802000_57.3.2000918.3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rmed.2017.04.013","article-title":"Effect of a single exacerbation on decline in lung function in COPD","volume":"128","author":"Halpin","year":"2017","journal-title":"Respir Med"},{"key":"2026061109101802000_57.3.2000918.4","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"2026061109101802000_57.3.2000918.5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/COPD.S103817","article-title":"Symptoms and lung function decline in a middle-aged cohort of males and females in Australia","volume":"11","author":"Abramson","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026061109101802000_57.3.2000918.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.08.001"},{"key":"2026061109101802000_57.3.2000918.7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","article-title":"Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk","volume":"197","author":"Calverley","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061109101802000_57.3.2000918.8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061109101802000_57.3.2000918.9","doi-asserted-by":"publisher","DOI":"10.1177\/1753465817750524"},{"key":"2026061109101802000_57.3.2000918.10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1042\/CS20160043","article-title":"COPD and stroke: are systemic inflammation and oxidative stress the missing links?","volume":"130","author":"Austin","year":"2016","journal-title":"Clin Sci"},{"key":"2026061109101802000_57.3.2000918.11","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2018"},{"key":"2026061109101802000_57.3.2000918.12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ntr\/ntz114","article-title":"Electronic cigarette use and cigarette abstinence over 2 years among U.S. smokers in the Population Assessment of Tobacco and Health Study","volume":"22","author":"Kalkhoran","year":"2019","journal-title":"Nicotine Tob Res"},{"key":"2026061109101802000_57.3.2000918.13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ntr\/nty077","article-title":"Smoking, systemic inflammation, and airflow limitation: a Mendelian randomization analysis of 98 085 individuals from the general population","volume":"21","author":"\u00c7olak","year":"2018","journal-title":"Nicotine Tob Res"},{"key":"2026061109101802000_57.3.2000918.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs016"},{"key":"2026061109101802000_57.3.2000918.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.12.006"},{"key":"2026061109101802000_57.3.2000918.16","doi-asserted-by":"crossref","first-page":"e010672","DOI":"10.1161\/JAHA.118.010672","article-title":"Lung function in young adults and risk of cardiovascular events over 29 years: the CARDIA study","volume":"7","author":"Cuttica","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026061109101802000_57.3.2000918.17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12931-018-0920-y","article-title":"Association of lung function with cardiovascular risk: a cohort study","volume":"19","author":"Wang","year":"2018","journal-title":"Respir Res"},{"key":"2026061109101802000_57.3.2000918.18","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.135392"},{"key":"2026061109101802000_57.3.2000918.19","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200404-032MS"},{"key":"2026061109101802000_57.3.2000918.20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.6.1952"},{"key":"2026061109101802000_57.3.2000918.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.049"},{"key":"2026061109101802000_57.3.2000918.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2026061109101802000_57.3.2000918.23","first-page":"974","article-title":"Longitudinal changes in forced expiratory volume in one second in adults","volume":"133","author":"Burrows","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2026061109101802000_57.3.2000918.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005540"},{"key":"2026061109101802000_57.3.2000918.25","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S133891"},{"key":"2026061109101802000_57.3.2000918.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2029OC"},{"key":"2026061109101802000_57.3.2000918.27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2147\/COPD.S242809","article-title":"FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease","volume":"15","author":"Bikov","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026061109101802000_57.3.2000918.28","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease. https:\/\/goldcopd.org. Date last accessed: September 9, 2019."},{"key":"2026061109101802000_57.3.2000918.29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1513\/AnnalsATS.201710-815OC","article-title":"Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease","volume":"15","author":"Rothnie","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026061109101802000_57.3.2000918.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2029"},{"key":"2026061109101802000_57.3.2000918.31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. a post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061109101802000_57.3.2000918.32","first-page":"217","article-title":"No association between exacerbation frequency and stroke in patients with COPD","volume":"11","author":"Windsor","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026061109101802000_57.3.2000918.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151357"},{"key":"2026061109101802000_57.3.2000918.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0831OC"},{"key":"2026061109101802000_57.3.2000918.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0337ST"},{"key":"2026061109101802000_57.3.2000918.36","doi-asserted-by":"publisher","DOI":"10.1080\/02770900500448738"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00918-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:10:29Z","timestamp":1781194229000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00918-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,4]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1183\/13993003.00918-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00918-2020","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/13993003.00918-2020.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/13993003.00918-2020.shareable1","asserted-by":"subject"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}